Under construction – not a live service
Sign in
Not yet taking people in PortugalPhase 3

Long-term safety of admilparant in people with pulmonary fibrosis

Checks long-term safety of admilparant in people who finished earlier pulmonary fibrosis studies.

Key facts

Who runs it
Bristol-Myers Squibb
Where
Lisbon, Loures, Porto, and Vila Nova de Gaia, PortugalSee the 5 sitesAlso in 29 other countries, 298 sites
Trial code
Registry title
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
Status
Not yet recruiting
Phase
Phase 3
People taking part
2,380 people, planned
Starts
16 Dec 2026
Expected to end
30 Mar 2030
Type of study
Interventional
Treatments tested
  • BMS-986278
Record updated
30 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with pulmonary fibrosis who took part in the earlier studies IM027068 (idiopathic pulmonary fibrosis) or IM0271015 (progressive pulmonary fibrosis). It tests the long-term safety of Admilparant.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Pulmonary fibrosis: idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). People must have taken part in the earlier study for their type.
Earlier treatment
People must have taken part in the earlier study IM027068 or IM0271015. They cannot have stopped treatment for good by withdrawing consent in that study.

Main reasons for not taking part

  • Any disease or condition that the investigator thinks is an unacceptable safety risk
  • Any side effect that led to permanent stop of the study drug in the earlier study
  • Heart failure symptoms at rest
  • History of lung reduction surgery or lung transplant
  • Known pulmonary arterial hypertension (PAH) on single-drug therapy that now needs several drugs

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Participants must have participated in either IM027068 or IM0271015 without discontinuing treatment permanently due to withdrawal of informed consent in either IM027068 or IM0271015

Who cannot take part

  • Any disease/condition that, in the investigator's judgment, may pose an unacceptable safety risk for study participation
  • Exhibit symptoms of heart failure at rest
  • History of lung reduction surgery or lung transplant
  • Participants with known PAH (Pulmonary Arterial Hypertension) who has been on single-drug therapy that now requires multi-drug therapy
  • Any AE that resulted in permanent discontinuation of IMP in IM027068 or IM0271015
  • Other protocol-defined Inclusion/Exclusion criteria apply

Where in Portugal

Also in 29 other countries, 298 sites

  • Unidade Local De Saude De Santa Maria E.P.E.Lisbon, PortugalNot yet recruiting
  • Unidade Local De Saude De Loures-Odivelas EPELoures, PortugalNot yet recruiting
  • Unidade Local De Saude De Santo Antonio E.P.E.Porto, PortugalNot yet recruiting
  • Unidade Local de Saude de Sao Joao E.P.E.Porto, PortugalNot yet recruiting
  • Unidade Local de Saúde de Gaia/Espinho, E. P. EVila Nova de Gaia, PortugalNot yet recruiting

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).

The group in the trial

  • BMS-986278 ArmTreatment being tested

    Treatment: BMS-986278

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
Plain-language title
Long-term safety of admilparant in people with pulmonary fibrosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
30 October 2026